GlaxoSmithKline PLC ADR (GSK) - Total Liabilities
Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) has total liabilities worth $59.93 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GlaxoSmithKline PLC ADR - Total Liabilities Trend (1985–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's total liabilities have evolved over time, based on quarterly financial data. See GlaxoSmithKline PLC ADR (GSK) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
GlaxoSmithKline PLC ADR Competitors by Total Liabilities
The table below lists competitors of GlaxoSmithKline PLC ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PDD Holdings Inc.
NASDAQ:PDD
|
USA | $215.27 Billion |
|
Altria Group
NYSE:MO
|
USA | $38.47 Billion |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
Germany | €833.36 Billion |
|
China Merchants Bank Co Ltd
SHG:600036
|
China | CN¥11.36 Trillion |
|
Starbucks Corporation
NASDAQ:SBUX
|
USA | $39.02 Billion |
|
HDFC Bank Limited
F:HDFA
|
Germany | €38.93 Trillion |
|
Parker-Hannifin Corporation
NYSE:PH
|
USA | $16.06 Billion |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
Germany | €1.59 Trillion |
Liability Composition Analysis (1985–2025)
This chart breaks down GlaxoSmithKline PLC ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GSK stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlaxoSmithKline PLC ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlaxoSmithKline PLC ADR (1985–2025)
The table below shows the annual total liabilities of GlaxoSmithKline PLC ADR from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $45.02 Billion | -2.94% |
| 2024-12-31 | $46.38 Billion | -21.27% |
| 2023-12-31 | $58.91 Billion | +17.70% |
| 2022-12-31 | $50.05 Billion | -36.03% |
| 2021-12-31 | $78.23 Billion | -4.01% |
| 2020-12-31 | $81.50 Billion | +0.31% |
| 2019-12-31 | $81.25 Billion | +49.38% |
| 2018-12-31 | $54.39 Billion | +2.84% |
| 2017-12-31 | $52.89 Billion | -2.27% |
| 2016-12-31 | $54.12 Billion | +21.43% |
| 2015-12-31 | $44.57 Billion | +24.79% |
| 2014-12-31 | $35.72 Billion | +4.20% |
| 2013-12-31 | $34.27 Billion | -1.31% |
| 2012-12-31 | $34.73 Billion | +7.67% |
| 2011-12-31 | $32.25 Billion | -0.17% |
| 2010-12-31 | $32.31 Billion | +0.58% |
| 2009-12-31 | $32.12 Billion | +3.36% |
| 2008-12-31 | $31.07 Billion | +47.32% |
| 2007-12-31 | $21.09 Billion | +32.62% |
| 2006-12-31 | $15.90 Billion | -18.97% |
| 2005-12-31 | $19.63 Billion | +15.41% |
| 2004-12-31 | $17.01 Billion | +9.80% |
| 2003-12-31 | $15.49 Billion | +3.69% |
| 2002-12-31 | $14.94 Billion | +10.10% |
| 2001-12-31 | $13.57 Billion | +7.39% |
| 2000-12-31 | $12.63 Billion | +74.66% |
| 1999-12-31 | $7.23 Billion | +9.97% |
| 1998-12-31 | $6.58 Billion | +0.47% |
| 1997-12-31 | $6.55 Billion | -7.10% |
| 1996-12-31 | $7.05 Billion | -15.30% |
| 1995-12-31 | $8.32 Billion | +10.53% |
| 1994-12-31 | $7.53 Billion | +174.92% |
| 1993-12-31 | $2.74 Billion | -2.25% |
| 1992-12-31 | $2.80 Billion | +37.10% |
| 1991-12-31 | $2.04 Billion | -17.02% |
| 1990-12-31 | $2.46 Billion | +45.94% |
| 1989-12-31 | $1.69 Billion | +45.93% |
| 1988-12-31 | $1.16 Billion | +8.65% |
| 1987-12-31 | $1.06 Billion | +19.02% |
| 1986-12-31 | $894.00 Million | +27.17% |
| 1985-12-31 | $703.00 Million | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more